The chief executive officer, Edward Kaye, of Cambridge, Mass.-based Sarepta Therapeutics (SRPT) recently indicated the company is looking to acquire a drug to treat Duchenne muscular dystrophy (DMD).   On June 29, 2015, Sarepta announced it had completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) […]

One U.S. biotech company is celebrating Independence Day weekend with a fresh $1 billion in cash from a corporate partner, which it was able to secure without giving up its corporate independence. For more, read on: Juno Secures $1B in Cancer Deal With Celgene Seattle-based Juno Therapeutics was the talk of the industry this week. […]